Full Prescribing Information
Click here to download the Full Prescribing Information for TOPAMAX as a PDF file.
Download the free Adobe® Reader® plugin.
Click here to download the Full Prescribing Information for TOPAMAX as a PDF file.
Download the free Adobe® Reader® plugin.
Attention TOPAMAX Patients and Medical Professionals
Dispensing errors have been reported between TOPAMAX® (topiramate) tablets and Toprol-xl® (metoprolol succinate) extended-release tablets.
Please be sure to check your tablets to ensure you are taking the right medicine.
*Toprol-xl is a registered trademark of the AstraZeneca group of companies.
TOPAMAX is approved for migraine prevention in adults only.
TOPAMAX is not used to stop a migraine after it starts.
IMPORTANT SAFETY INFORMATION
Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation (rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness. Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic, untreated metabolic acidosis may increase the risk for kidney stones or bone disease.
Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness, dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not treated right away.
More common side effects are tingling in arms and legs, loss of appetite, tiredness, nausea, diarrhea, taste change and weight loss.
Tell your doctor about other medications you take. Please see full U.S. Prescribing Information.
© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2008. All rights reserved. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by Ortho-McNeil Neurologics, division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents.
This information is intended for the use of our customers, patients and healthcare professionals in the United States and Puerto Rico only.
Ortho-McNeil-Janssen Pharmaceuticals, Inc. recognizes that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The prescribing information included here may not be appropriate for use outside the United States and Puerto Rico.
Capitalized product names are trademarks of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
